Table 2.1: Share of vaccines segment in anti-infectives market, US/Europe*, 2002-2003 38
Table 2.2: Sales of vaccine products by indication and country ($m), 2002-03 39
Table 2.3: Top 10 vaccines in US/Europe* by sales ($m), 2002-03 40
Table 3.4: US/European* sales of MMR vaccines ($m), 2002-03 52
Table 3.5: US/European* sales of combination vaccines with a tetanus component ($m), 2002-03 56
Table 3.6: US/European* sales of pneumococcal vaccines ($m), 2002-03 62
Table 3.7: US/European* sales of meningococcal vaccines ($m), 2002-03 67
Table 3.8: US/European* sales of other pediatric vaccines ($m), 2002-03 69
Table 4.9: US/European* sales of hepatitis vaccines ($m), 2002-03 80
Table 4.10: US/European* sales of influenza vaccines ($m), 2002-03 88
Table 4.11: US/European* sales of other adult vaccines ($m), 2002-03 95
Table 5.12: Merck’s vaccines R&D pipeline and global sales forecasts, 2007 & 2010 102
Table 5.13: Global* sales of Wyeth’s marketed vaccines portfolio ($m), 2002-03 106
Table 5.14: Wyeth’s vaccines R&D pipeline and global sales forecasts, 2007 & 2010 107
Table 5.15: Global* sales of GSK’s marketed vaccines portfolio ($m), 2002-03 108
Table 5.16: GSK’s vaccines R&D pipeline and global sales forecasts, 2007 & 2010 109
Table 5.17: Global* sales of Sanofi-Aventis’ marketed vaccines portfolio ($m), 2002-03 114
Table 5.18: Sanofi-Aventis’ vaccines R&D pipeline and global sales forecasts, 2007 & 2010 115
Table 5.19: Sales of Chiron’s marketed vaccines portfolio ($m), 2002-03 118
Table 5.20: Chiron’s vaccines R&D pipeline and global sales forecasts, 2007 & 2010 119
Figure 1.1: Timeline of vaccine development 21
Figure 2.2: Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003 41
Figure 3.3: Pediatric vaccination schedule for the US and 5 major European markets, 2004 46
Figure 3.4: Percentage of target population vaccinated the US, 5EU and global, 2003 47
Figure 3.5: Pediatric target population, 2005 49
Figure 3.6: MMR II SWOT analysis 53
Figure 3.7: Priorix SWOT analysis 55
Figure 3.8: Infanrix & Infanrix HeXa SWOT analysis 58
Figure 3.9: Pediarix SWOT analysis 59
Figure 3.10: Hexavac & Pentacel SWOT analysis 60
Figure 3.11: Prevnar SWOT analysis 64
Figure 3.12: Pneumovax 23 SWOT analysis 65
Figure 3.13: Varivax SWOT analysis 70
Figure 3.14: Comvax SWOT analysis 72
Figure 4.15: Adolescent population in the US and 5 major European markets, 2005 76
Figure 4.16: Elderly population in the US and 5 major European markets, 2005 77
Figure 4.17: Number of deaths from influenza and pneumonia in the US, 1995-2002 78
Figure 4.18: Engerix-B SWOT analysis 82
Figure 4.19: Recombivax HB SWOT analysis 83
Figure 4.20: Twinrix SWOT analysis 85
Figure 4.21: Havrix SWOT analysis 86
Figure 4.22: Fluzone SWOT analysis 90
Figure 4.23: Fluvirin SWOT analysis 92
Figure 4.24: FluMist SWOT analysis 93
Figure 5.25: Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003 100
Figure 5.26: Merck & Co’s global* therapeutic focus, 2003 & 2010 101
Figure 5.27: Wyeth’s global* therapeutic focus, 2003 & 2010 105
Figure 5.28: GSK’s global* therapeutic focus, 2003 & 2010 108
Figure 5.29: Sanofi-Aventis’ global* therapeutic focus, 2003 & 2010 113
Figure 5.30: Chiron’s global* therapeutic focus, 2003 & 2010 117
[Tabellenverzeichnis ausblenden]
